Why Purple (PRPL) Stock Is Trading Lower Today

Purple (PRPL) shares fell 24.6% after the company reported Q2 revenue of $98.27 million, down 6.5% year over year and below Wall Street expectations. Adjusted EPS was a loss of $1.52, better than forecast. Purple kept full-year revenue guidance around $430 million, but investors focused on the quarterly sales miss.

Original reporting
Published Aug 11, 2026, 5:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 11, 2026, 5:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Why Purple (PRPL) Stock Is Trading Lower Today — source image
Decision brief

The 30-second read

$PRPLBearishMed
01

Why it matters

The article frames the move as driven by the quarterly sales shortfall, with investors discounting the stable full-year forecast.

02

Market read

A large single-day drop tied to a quarterly revenue miss creates a near-term trading setup around whether the market will accept the stable full-year outlook.

03

What to watch

Adjusted EPS improved versus expectations, which could support downside stabilization if investors later refocus on profitability rather than only top-line.

Relevance 8/10Novelty 6/10Timing: afternoon session after Q2 results and guidance

Background

Purple reported Q2 revenue down 6.5% year-over-year to $98.27M and guided full-year revenue to about $430M.

Company-level read

Ticker impact

$PRPLBearishMedium confidence
Context

Purple shares fell 24.6% after Q2 revenue of $98.27M missed expectations, despite a stable full-year sales forecast.

Expected impact

Near-term downside pressure likely persists until investors see evidence of improving quarterly demand or margin trajectory.

Evidence & confidence

The article attributes the large afternoon drop directly to the Q2 top-line miss, while noting the market focused on current-quarter weakness rather than the full-year stability.

Market effects

Highlights sensitivity of consumer retail bedding names to quarterly revenue misses versus stable full-year guidance.

No specific regional spillover described.

No global macro or cross-border linkage described.

Counterpoint

Full-year revenue guidance is described as aligned with estimates, so the selloff may be overdone if the quarter is a temporary demand dip.

Key entities

  • Purple

    Bedding and comfort retailer whose Q2 revenue miss triggered a 24.6% afternoon decline.

Related articles

$PRPLMed

Purple Innovation Reports Third Quarter 2026 Results

Purple Innovation, Inc. (PRPL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CONFIDENTIAL DRAFT Purple Innovation Reports Third Quarter 2026 Results Positive Operating Cash Flow for the Third Consecutive Quarter Preparing for Major Mattress Portfolio Refresh to Strengthen Performance in 2027 Lehi, Utah, November 4, 2026 – Purple Innovation, I

$PRPLMed

Purple Innovation Reports Second Quarter 2026 Results

Purple Innovation, Inc. (PRPL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Purple Innovation Reports Second Quarter 2026 Results Showroom Revenue Up 16.6% and Comparable Revenue Up 18% GAAP Net Loss of $3.2 Million in the Second Quarter Adjusted EBITDA Improves $4.4 Million to $2.1 Million Regains Compliance with Nasdaq Minimum Bid Price Re

$PRPLMedAI 8/10

Purple (NASDAQ:PRPL) Misses Q2 CY2026 Sales Expectations

Purple (NASDAQ:PRPL) reported Q2 CY2026 revenue of $98.27 million, down 6.5% year on year, missing market expectations. Non-GAAP adjusted EPS was -$1.52, better than analysts’ consensus. For next quarter, management guided revenue to $430 million at the midpoint. The article also notes negative operating margin and ongoing revenue decline.

Med

TELUS (TU) Q3 2026 Earnings Call Transcript

TELUS (TU) outlined three key priorities during its Q3 2026 earnings call: strengthening its financial foundation, honing operational discipline, and deploying resources for growth. The company aims to reduce debt, achieve a net debt to adjusted EBITDA leverage ratio of 3x or lower by 2028, and target $900 million in annualized cash savings by 2028. TELUS plans to monetize non-core assets, streamline operations, and invest in its PureFibre network for growth in AI infrastructure.

$PAHCMedAI 8/10

Phibro Animal (PAHC) Q1 2027 Earnings Call Transcript

Phibro Animal Health (PAHC) reported Q1 2027 sales growth of 6% to $386.8M and adjusted EBITDA growth of 4% to $64.3M. Performance Products and Mineral Nutrition segments drove growth, while Animal Health saw a 3% increase. The company maintained its full-year guidance and expects protein demand to grow, despite near-term pressure on producer profitability.

$NOGMed

Northern Oil And Gas (NOG) Beat Expectations, But Is The Stock Still Cheap?

Northern Oil and Gas (NOG) reported record Q3 production and EBITDA, beating earnings expectations. The company raised its 2026 output guidance. Despite a 19.44% drop in the 7-day share price, the 1-year return is 14.36% and the 5-year return is 22.67%. The stock is trading at $22.84, with some analysts valuing it at $30.44, suggesting a 25% undervaluation. The company's focus on capital allocation and asset mix aims to support future earnings.